199 related articles for article (PubMed ID: 17117598)
1. A two-stage decision analysis to assess the cost of 5-aminosalicylic acid failure and the economics of balsalazide versus mesalamine in the treatment of ulcerative colitis.
Mackowiak JI
Manag Care Interface; 2006 Oct; 19(10):39-46, 56. PubMed ID: 17117598
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of 5-aminosalicylic acid therapy for maintenance of remission in ulcerative colitis.
Yen EF; Kane SV; Ladabaum U
Am J Gastroenterol; 2008 Dec; 103(12):3094-105. PubMed ID: 18775007
[TBL] [Abstract][Full Text] [Related]
3. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.
Pruitt R; Hanson J; Safdi M; Wruble L; Hardi R; Johanson J; Koval G; Riff D; Winston B; Cross A; Doty P; Johnson LK
Am J Gastroenterol; 2002 Dec; 97(12):3078-86. PubMed ID: 12492193
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
[TBL] [Abstract][Full Text] [Related]
5. Balsalazide in treating colonic diseases.
Tursi A
Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1555-63. PubMed ID: 19708827
[TBL] [Abstract][Full Text] [Related]
6. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
Sandborn WJ
Rev Gastroenterol Disord; 2006; 6(2):97-105. PubMed ID: 16699478
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
Scherl EJ; Pruitt R; Gordon GL; Lamet M; Shaw A; Huang S; Mareya S; Forbes WP
Am J Gastroenterol; 2009 Jun; 104(6):1452-9. PubMed ID: 19491859
[TBL] [Abstract][Full Text] [Related]
8. Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis.
Yen L; Wu J; Hodgkins PL; Cohen RD; Nichol MB
J Manag Care Pharm; 2012; 18(9):701-12. PubMed ID: 23206213
[TBL] [Abstract][Full Text] [Related]
9. Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations?
Sandborn WJ
J Clin Gastroenterol; 2008 Apr; 42(4):338-44. PubMed ID: 18277908
[TBL] [Abstract][Full Text] [Related]
10. Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis.
Piodi LP; Ulivieri FM; Cermesoni L; Cesana BM
Scand J Gastroenterol; 2004 Feb; 39(2):154-7. PubMed ID: 15000277
[TBL] [Abstract][Full Text] [Related]
11. Encapsulated mesalamine granules (Apriso) for ulcerative colitis.
Med Lett Drugs Ther; 2009 May; 51(1312):38-9. PubMed ID: 19448588
[TBL] [Abstract][Full Text] [Related]
12. Mesalamine restores angiogenic balance in experimental ulcerative colitis by reducing expression of endostatin and angiostatin: novel molecular mechanism for therapeutic action of mesalamine.
Deng X; Tolstanova G; Khomenko T; Chen L; Tarnawski A; Szabo S; Sandor Z
J Pharmacol Exp Ther; 2009 Dec; 331(3):1071-8. PubMed ID: 19762547
[TBL] [Abstract][Full Text] [Related]
13. NAT1 genotypes do not predict response to mesalamine in patients with ulcerative colitis.
Hausmann M; Paul G; Menzel K; Brunner-Ploss R; Falk W; Schölmerich J; Herfarth H; Rogler G
Z Gastroenterol; 2008 Mar; 46(3):259-65. PubMed ID: 18322880
[TBL] [Abstract][Full Text] [Related]
14. Treatment of ulcerative colitis with balsalazide: response to editorial by Drs. Farrell and Peppercorn and letter to the editor by Dr. Hanauer.
Johnson LK; Pruitt RE; Green JR
Am J Gastroenterol; 2003 Jan; 98(1):216-9. PubMed ID: 12526969
[No Abstract] [Full Text] [Related]
15. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis.
Hanauer SB
Aliment Pharmacol Ther; 2006 Oct; 24 Suppl 3():37-40. PubMed ID: 16961743
[TBL] [Abstract][Full Text] [Related]
16. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
Sandborn WJ; Regula J; Feagan BG; Belousova E; Jojic N; Lukas M; Yacyshyn B; Krzeski P; Yeh CH; Messer CA; Hanauer SB
Gastroenterology; 2009 Dec; 137(6):1934-43.e1-3. PubMed ID: 19766640
[TBL] [Abstract][Full Text] [Related]
17. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H
Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
[TBL] [Abstract][Full Text] [Related]
18. Mesalamine with MMX technology for the treatment of ulcerative colitis.
Schreiber S; Kamm MA; Lichtenstein GR
Expert Rev Gastroenterol Hepatol; 2008 Jun; 2(3):299-314. PubMed ID: 19072380
[TBL] [Abstract][Full Text] [Related]
19. Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis--methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa.
Lichtenstein GR; Kamm MA
Aliment Pharmacol Ther; 2008 Sep; 28(6):663-73. PubMed ID: 18532992
[TBL] [Abstract][Full Text] [Related]
20. Ulcerative proctitis: a review of pharmacotherapy and management.
Lakatos PL; Lakatos L
Expert Opin Pharmacother; 2008 Apr; 9(5):741-9. PubMed ID: 18345952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
